Serious adverse events · Adult patients with myelodysplastic syndromes and thrombocytopenia
It is very uncertain whether thrombopoietin mimetics changes serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Serious adverse events · adults with atrial fibrillation
It is very uncertain whether exercise changes serious adverse events compared with no exercise (very low certainty).
1 finding from 1 review
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · participants with unresectable hepatocellular carcinoma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with primary sclerosing cholangitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · people with pressure ulcers
It is very uncertain whether the intervention changes serious adverse events (very low certainty).
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · aged 18 years and older undergoing elective surgery at any surgical site
1 finding from 1 review
Serious adverse events · people with cirrhosis and hepatorenal syndrome
It is very uncertain whether terlipressin changes serious adverse events compared with other vasoactive drugs (very low certainty).
1 finding from 1 review
RR 0.96 [0.88, 1.06]
474 participants
Very low
Serious adverse events · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with acute HBV infection
1 finding from 1 review
Serious adverse events · people with hereditary haemochromatosis
1 finding from 1 review
Serious adverse events · adults with neuropathic pain
1 finding from 1 review
Serious adverse events ( · Individuals with peripheral arterial disease
Growth factors showed no clear difference in serious adverse events ( compared with placebo or no therapy (moderate certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with single‐dose, postoperative MMC‐PD (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether single‐dose, preoperative MMC‐EMDA changes serious adverse events compared with TURBT alone (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
1 finding from 1 review
Serious adverse events
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review